MedGenome vs Regard AI

Neither company has publicly disclosed a valuation, making a definitive size comparison difficult. MedGenome employs 200-500 people, while Regard AI has 50-200 employees.

MedGenome has raised more in total funding at $50M, compared to Regard AI's $30M — a gap of $20M.

MedGenome holds the higher Awaira Score at 63/100, compared to Regard AI's 55/100. The Awaira Score is a composite metric factoring in valuation, funding, stage, team size, and market presence — a 8-point gap that reflects meaningful differences in scale or traction.

MedGenome was founded by Sam Santhosh in 2013. Regard AI's founder information is not currently available in our database.

MedGenome: MedGenome is a genomics and precision medicine company that combines next-generation sequencing with AI-powered data analysis to deliver clinical genomic testing for rare diseases, hereditary cancers, and pharmacogenomics. The company operates a NABL-accredited genomics laboratory and a bioinformatics platform that interprets variant data against proprietary South Asian population databases.\n\nThe company raised approximately $50M across Series B and C rounds from investors including Sequoia India and CDC Group, and serves hospitals, research institutions, and pharmaceutical companies across India and Southeast Asia. MedGenome has built one of the largest repositories of South Asian genomic data, which is clinically significant given that most reference genome databases are biased toward European populations.\n\nThe underrepresentation of South Asian genetic variation in global genomic databases creates both a clinical risk and a commercial opportunity. MedGenome's proprietary database of South Asian genomic variants and its AI-powered interpretation capabilities represent a durable competitive asset as personalized medicine adoption grows across the Indian healthcare system. Regard AI: Regard AI builds an AI clinical documentation assistant that integrates with hospital electronic health record systems to automatically identify potential diagnoses, surface relevant clinical evidence from patient records, and generate structured documentation for physician review. The system is designed to reduce the documentation burden on hospitalists and clinical teams while improving diagnostic completeness and coding accuracy.\n\nThe company raised approximately 30 million USD and has deployed across hospital systems focused on reducing physician administrative load, a problem that contributes to clinician burnout and documentation errors with downstream billing and quality implications. Regard operates as a background analysis layer that surfaces findings without requiring clinicians to change their existing EHR workflow.\n\nClinical documentation AI sits at the intersection of physician workflow optimization and revenue cycle management, giving it a dual value proposition that justifies enterprise procurement from both clinical operations and hospital finance departments. Regard competes with Nuance DAX, Abridge, and other ambient documentation tools, but its focus on diagnostic suggestion and coding completeness rather than pure transcription differentiates its clinical and financial value story.

MedGenome was founded first in 2013, giving it 4 years of additional market experience. Regard AI was founded later in 2017. In AI, even a year or two of head start can translate into significantly more training data, customer relationships, and institutional knowledge.

MedGenome has approximately 200-500 employees, while Regard AI has approximately 50-200. A larger team often signals higher revenue or venture backing, but in AI, smaller teams are increasingly capable of building at scale.

Yes, MedGenome and Regard AI are direct competitors — both operate in the AI Healthcare space and likely target overlapping customer segments. This comparison is especially relevant for buyers evaluating both platforms.